Is CRMD Stock a Buy Now After Strong Growth and New Risks?

Impact · against what's priced in

CorMedix has successfully transitioned to a commercial-stage company with strong 2025 revenue growth and a diversified portfolio. However, near-term upside is tempered by expected pricing pressure in the second half of 2026 as DefenCath reimbursement transitions to a post-payment add-on phase.

CRMD+0.30: No priced-in read yet
In context: Revenue jumped to $311.7 million in 2025 and the company has a liquid balance sheet of $178.1 million, though net pricing for DefenCath is expected to face pressure in H2 2026.
Read from the article alone

Is CRMD Stock a Buy Now After Strong Growth and New Risks?

revenue growth
healthcare
biotech
pharmaceuticals
CRMD
commercialization
profitability

Search tags

Is CRMD Stock a Buy Now After Strong Growth and New Risks?

What matters in this story

The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment

Is CRMD Stock a Buy Now After Strong Growth and New Risks?

What matters in this story

The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment

How each ticker is affected

Connected tickers

Track these names every morning.

Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX

Is CRMD Stock a Buy Now After Strong Growth and New Risks?

What matters in this story

Next reads from the same story arc

The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment

Is CRMD Stock a Buy Now After Strong Growth and New Risks?

What matters in this story

Next reads from the same story arc

The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment

How each ticker is affected

Connected tickers

Track these names every morning.

Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX